Objective
A European biotech company has enlisted eQuantX to provide continuous support for maximizing the value of their pipeline. This involves developing strategies for early and late-phase assets through proactive assessment of disease areas of interest, early-phase product planning, and in-licensing activities. The partnership also includes exploring reimbursement opportunities for a portfolio of products in key markets and supporting successful commercialization, particularly in EU5. The focus of assessment includes Solid Tumors and Hematological Malignancies, encompassing R&D, clinical trials, and market access, while staying attuned to industry trends
Approach
Data Preparation & Standardization: Utilizing multiple internal and external data sources, we received inputs from the R&D and commercial departments. We gathered information at the regional level from press releases, company websites, or other source data for transactions. Additionally, we employed paid data sources such as IMS Midas, CapitalIQ, investor reports, etc., to collect data on volumes, shares, prices, costs, etc. Standardizing data with respect to the economy, currency, overall market growth, etc., was a crucial step. The final outcome included estimating the potential market size and growth opportunities for the existing and new portfolio of the client
Scenarios Analysis & Alternate Investment Evaluations: Test projection robustness and compare products through scenario metrics that analyzed changes over time, such as development cost by year and revenue by year. This involved comparing portfolios for each time period, assessing the portfolio’s costs and revenue against each other and against a target portfolio. Additionally, the task included developing alternative investment scenarios, such as residue, discontinuation, sustaining share, growth, or maximizing potential.
Outcome
The research output provided our client with a refined and well-informed strategy for their early and late-stage, in-licensed assets. This involves the development and validation of strategic product portfolio plans, thorough scenario planning, and continuous commercial assessments. These efforts ultimately enhanced decision-making processes, optimized the portfolio’s potential, and ensured a robust and adaptive approach to the evolving landscape of their in-licensed phase assets.
